IISc-incubated Mynvax to get funding to bring “warm” Covid vaccine to market
The Hindu
The company was developing novel recombinant vaccines for COVID-19 and human influenza and would use the proceeds to further clinical development for the same
Mynvax, a vaccine technology startup, incubated by the Society for Innovation and Development (SID) at the Indian Institute of Science, has signed an agreement to raise $4.2 million (₹31 crore) in its Series A round of financing led by Accel to bring thermotolerant Covid vaccine to the market. The company was developing novel recombinant vaccines for COVID-19 and human influenza and would use the proceeds to further clinical development for the same, it said on Monday. LetsVenture and a few early stage angel investors also participated in this round, which received the backing of its pre-Series A investors such as 1Crowd, Kotak Investment Advisors and other angel investors.More Related News

Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.












